Navigation Links
Epilepsy Drug May Boost Birth Defect Risk
Date:7/21/2008

Women who take topiramate should discuss preconception planning with their doctor

MONDAY, July 21 (HealthDay News) -- Pregnant women who use the epilepsy drug topiramate alone or in combination with other epilepsy drugs may be increasing their risk of birth defects, British researchers report.

Topiramate (brand name Topamax) is a common anti-seizure medication used by many with epilepsy. It's also used to treat migraine headaches. Many similar drugs also increase the risk of birth defects, but until this report, the link between birth defects and topiramate had not been well studied.

"More research needs to be done to confirm these results, especially since it was a small study," lead researcher John Craig, of the Royal Group of Hospitals in Belfast, Northern Ireland, said in a news release from the American Academy of Neurology. "But these results should also get the attention of women with migraine and their doctors, since topiramate is also used for preventing migraine, which is an even more common condition that also occurs frequently in women of childbearing age."

The report is published in the July 22 issue of the journal Neurology.

For the study, the researchers collected data on women who became pregnant while taking topiramate alone or in combination with other epilepsy drugs.

Craig's team found that of the 178 babies born, 16 (4.8 percent) suffered from major birth defects. Among the babies with birth defects, three of the mothers were taking topiramate exclusively, while 13 were taking topiramate plus other epilepsy drugs.

Four of the babies had cleft palettes or cleft lips. That's a rate 11 times higher than one would expect among women not taking the drug, the researchers said.

Among male babies, four had genital defects, with two classified as "major defects." That's a rate 14 times higher than normal, the researchers reported.

The incidence of birth defects among women taking topiramate was higher than the rate of birth defects in the general population, which is about 1 percent to 2.5 percent. And there were more birth defects among women taking topiramate along with the epilepsy drug valproate, compared with women taking topiramate and another epilepsy drug.

Despite the risk, it's important that women maintain effective epilepsy control during pregnancy, because seizures can also harm the fetus. The risk of birth defects may be different among women taking topiramate to treat migraines, but these women should be monitored as well, the researchers said.

Dr. Orrin Devinsky, a professor of neurology, neurosurgery and psychiatry, and director of the New York University Epilepsy Center, said this study underscores the need for all women of childbearing years who take antiepileptic drugs to discuss preconception planning with their physician.

"All women should clearly understand the risks and benefits of their therapy," Devinsky said. "Until more information is available, topiramate use in women who plan on conceiving should be restricted to those in whom the drug is definitely needed for seizure control or other indications. Also, the mother should be informed of the potential risks to her child."

Another epilepsy expert, Dr. Edward Barry Bromfield, chief of the Division of Epilepsy at Brigham and Women's Hospital in Boston, agreed that women should be warned about the potential side effects of the drug.

"Women with epilepsy, if they depend on this drug to control their convulsive seizures, they should definitely continue it," Bromfield said. "If they are taking it for migraine prevention, chances are they would want to discontinue it before conception," he said.

More information

For more on epilepsy, visit the U.S. National Library of Medicine.



SOURCES: Orrin Devinsky, M.D., professor of neurology, neurosurgery and psychiatry, and director, New York University Epilepsy Center, New York City; Edward Barry Bromfield, M.D., chief, Division of Epilepsy, Brigham and Women's Hospital, Boston; July 22, 2008, Neurology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Some Epilepsy Patients Are Good Candidates for Surgery
2. Ovation further advances development pipeline with new phase III epilepsy study
3. A childs IQ could be affected by maternal epilepsy
4. Research shows how genetic mutation causes epilepsy in infants
5. Epilepsy Drug Holds Promise as Treatment for Alcoholism
6. Lamotrigine May Reduce Epilepsy Seizures
7. Childhood epilepsy research offers new hope for seizure control
8. Epilepsy drugs may cause sexual disorders
9. Quality of life study examines burden of epilepsy
10. Epilepsy-induced brain cell damage prevented in the laboratory
11. Epilepsy genes may cancel each other
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology: